IRCT20150721023282N25 IRCT 2023-06-15 Esfahan University of Medical Sciences Evaluation of the effectiveness of curcumin in improving the symptoms of patients with chronic coronary syndrome Evaluation of the effectiveness of curcumin in improving the symptoms of patients with chronic coronary syndrome: a randomized double-blind placebo-controlled clinical trial 2023-07-06 anticipated 44 Complete https://irct.ir/trial/65891 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: Block randomization method using blocks of size 4 will be used. So that all possible sequences of two drug and two placebo in each block will be made with each block being numbered. Then, using random number table, the blocks will be selected randomly and the patients will be assigned to the two groups of drug and placebo according to the the blocks sequences, Blinding description: For blinding, drug boxes containing curcumin and placebo, which are completely similar, will be coded by the manufacturing company, and the information related to the drug content of each code (drug or placebo) will be available only to that center until the end of the data analysis. 3 Chronic coronary syndrome. Intervention 1: Intervention group: Curcumin soft capsule (Turmepro produced by Gol Daro Pharmaceutical Company) 250 mg every 8 hours for 8 weeks. Intervention 2: Control group: placebo soft capsule (Turmepro produced by Gol Daro Pharmaceutical Company) 250 mg every 8 hours for 8 weeks. No - There is not a plan to make this available Justification or reason for not sharing IPD is Confidentiality of patient information